RecruitingPhase 1NCT04906460
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Studying Duchenne muscular dystrophy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Wave Life Sciences Ltd.
- Principal Investigator
- Medical Director, MDWave Life Sciences
- Intervention
- WVE-N531(drug)
- Enrollment
- 26 enrolled
- Eligibility
- 4-18 years · MALE
- Timeline
- 2021 – 2026
Study locations (5)
- Arkansas Children's Hospital, Little Rock, Arkansas, United States
- Rare Disease Research LLC, Atlanta, Georgia, United States
- Istiklal Hospital/ Clinical Research Unit, Amman, Jordan
- The Specialty Hospital (TSH)/ Advanced Clinical Center, Amman, Jordan
- Oxford Children's Hospital, Oxford University Hospitals NHS Foundation Trust, Headington, Oxford, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04906460 on ClinicalTrials.govOther trials for Duchenne muscular dystrophy
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07332013Urinary Titin Biomarker in DMDChildren's Hospital of Philadelphia
- RECRUITINGNCT07092540The Baby Duchenne Study: Characterizing Developmental and Clinical Outcomes in the First Three Years in Children With Duchenne Muscular DystrophyUniversity of Rochester
- ENROLLING BY INVITATIONNANCT06887491The Effect of Dual-tasking Program on Cognitive and Physical Functions and Independence in Activities of Daily Living in Children With Duchenne Muscular Dystrophy: A Single-blind Randomized Controlled TrialLokman Hekim University
- ACTIVE NOT RECRUITINGPHASE1NCT07347548A Trial to Investigate the Safety and Pharmacokinetics of GRT6019 in Healthy Male ParticipantsGrünenthal GmbH
- ENROLLING BY INVITATIONPHASE2NCT07209332Open-Label Extension Study of WVE-N531 in Patients With Duchenne Muscular DystrophyWave Life Sciences Ltd.
- ACTIVE NOT RECRUITINGEARLY PHASE1NCT07282652A Study to Evaluate the Safety and Tolerability of RAG-18 in Pediatric Patients With Duchenne Muscular DystrophyPeking Union Medical College Hospital
- RECRUITINGPHASE2NCT07287189Phase 2 Study of SAT-3247 in Pediatric Ambulatory PatientsSatellos Bioscience, Inc.
- ENROLLING BY INVITATIONNCT07435116Duchenne Muscular Dystrophy and the Viscoelastic Properties of Upper Limb MusclesSanko University